Medipharm Labs Corp (LABS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 2,383 | 894 | 1,480 | 876 | 7,192 |
| Income taxes - deferred | 7 | -130 | 236 | 0 | 192 |
| Accounts receivable | 12,967 | 4,360 | -2,216 | 1,872 | -4,417 |
| Other Working Capital | 17,231 | 4,999 | 106 | -508 | 33,474 |
| Other Operating Activity | -36,633 | -10,366 | -2,556 | -8,215 | -43,765 |
| Operating Cash Flow | $-4,045 | $-243 | $-2,950 | $-5,975 | $-7,324 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -21 | 158 | 52 | 122 | N/A |
| Other Investing Activity | 301 | -115 | -184 | -278 | -31 |
| Investing Cash Flow | $280 | $43 | $-132 | $-156 | $-31 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -81 | -81 | -75 | -2,725 | -8,711 |
| Common Stock Issued | 0 | -190 | 0 | 31,107 | N/A |
| Other Financing Activity | 82 | -329 | 39 | 57 | -562 |
| Financing Cash Flow | $1 | $-600 | $-36 | $28,439 | $-9,273 |
| Exchange Rate Effect | -84 | 7 | -255 | -97 | N/A |
| Beginning Cash Position | 37,958 | 38,751 | 42,124 | 19,913 | 36,458 |
| End Cash Position | 34,110 | 37,958 | 38,751 | 42,124 | 19,913 |
| Net Cash Flow | $-3,764 | $-800 | $-3,118 | $22,308 | $-16,628 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,045 | -243 | -2,950 | -5,975 | -7,324 |
| Capital Expenditure | -206 | -115 | -184 | -278 | -90 |
| Free Cash Flow | -4,251 | -358 | -3,134 | -6,253 | -7,414 |